20 kinds of miraculous drugs have gone down the altar, and these drugs will be subject to key monitoring
4hw.com.cn: at the beginning of this year, the focus interview broadcast auxiliary drugs: from abuse to regular use caused industry shock, and the standardized use of auxiliary drugs became the focus of the society. After a few months, the first batch of national key drug monitoring catalogue was released.
On July 1, the official website of the National Health Commission issued the notice on printing and distributing the list of the first batch of national key monitored rational drug use drugs (chemical drugs and biological products). 20 drugs such as ganglioside, brain glycoside carnosine, olacetam, calf serum deproteinization, Salvia miltiorrhiza Ligustrazine and cinepazide maleate were included in the list of national key monitored drugs.
It is understood that most of these drugs are large varieties for clinical application. According to the statistics of the reporter of Securities Daily, among these 20 kinds of drugs, four varieties are the exclusive varieties of enterprises. For example, the manufacturer of compound coenzyme for injection is Beijing Shuanglu Pharmaceutical Co., Ltd.
Will this affect the product sales of listed companies? The reporter of Securities Daily contacted the Board Secretary Office of Shuanglu Pharmaceutical by telephone. A person from the company said that the company is also evaluating, and the specific impact depends on the implementation of the policy. Doctors will look at the clinical data of drugs and prescribe them.
First batch of key monitoring list released
The use of adjuvant drugs has always been the focus of social attention. Under the influence of policies such as medical insurance cost control, the water of adjuvant drugs has been gradually squeezed out.
Prior to this, Xinjiang and other provinces have published the catalogue of adjuvant drug monitoring. In December 2018, the National Health Commission issued the notice on doing a good job in the management of clinical application of adjuvant drugs, and the national version of the catalogue of adjuvant drugs is ready to come out.
On July 1, the official website of the National Health Commission issued the notice on printing and distributing the first batch of national key controlled rational drug use drug catalogue (chemical drugs and biological products), marking the upgrading of auxiliary drug use monitoring at the national level.
In the above notice, the National Health Commission requires all medical institutions to establish a drug management system focusing on monitoring rational drug use and strengthen the whole process management of the clinical application of drugs in the catalogue. Further standardize the prescription behavior of doctors, formulate medication guidelines or technical specifications for drugs included in the catalogue, and clearly specify the conditions and principles of clinical application. If there are relevant medication guidelines or guiding principles, they shall be implemented in strict accordance with the guidelines or principles. Carry out prescription review and prescription comment on all drugs included in the catalogue, and strengthen the publicity, feedback and utilization of prescription comment results. For the varieties with prominent unreasonable drug use problems, measures such as ranking and notification, rectification within a time limit, and removal from the drug supply catalogue of the institution shall be taken to ensure rational drug use.
It is worth mentioning that for chemical drugs and biological products not included in the catalogue, the above notice requires doctors to strictly implement the prescription management measures and other relevant provisions, reasonably select drug varieties, administration routes and dosage, and issue prescriptions in accordance with the indications, disease diagnosis and treatment standard guidelines and corresponding prescription authority specified in the drug instructions.
In addition, for traditional Chinese medicine, the above notice also points out that doctors of traditional Chinese medicine should prescribe traditional Chinese medicine in accordance with the guiding principles for the clinical application of proprietary Chinese medicine and the management norms of traditional Chinese medicine in hospitals, and in accordance with the basic principles of syndrome differentiation and treatment of traditional Chinese medicine.
While releasing the first batch of key drug monitoring catalogue, it is also very important to strengthen clinical monitoring.
According to the requirements of the National Health Commission, health administrative departments at all levels, competent departments of traditional Chinese medicine and medical institutions should establish and improve the monitoring and abnormal early warning system for clinical use of drugs. The clinical use of drugs included in the catalogue shall be taken as the assessment content of medical institutions and their main principals, combined with verification, review and evaluation and performance assessment of medical institutions, and the assessment results shall be publicized in time. For drugs that have not been included in the catalogue management, routine clinical use monitoring shall be done well. In case of abnormal increase in use, no indication, over dose use and other problems, early warning shall be strengthened and the causes shall be found. Those who violate laws and regulations shall be dealt with seriously.
Industry adjustment may accelerate
In an interview with the Securities Daily, an insider said that the release of the catalogue of auxiliary drugs involves the interests of enterprises. Once the catalogue is released, the national sales of these varieties will be affected.
The data show that the sales of the above 20 drugs exceed 100 million yuan, and the market sales of some varieties exceed 100 million yuan. The total market sales of these 20 drugs exceeded 10 billion yuan.
It is worth mentioning that some drugs are the exclusive varieties of enterprises. For example, Shuanglu pharmaceutical's compound coenzyme for injection is an important product of the company; The manufacturer of calf serum deproteinized injection is Jinzhou AoHong Pharmaceutical Co., Ltd; Jilin Sihuan Pharmaceutical Co., Ltd. is the manufacturer of troxerutin brain protein hydrolysate injection.
There are few manufacturers of some varieties, such as Jilin Zhenao Pharmaceutical Co., Ltd. and Jilin Sihuan Pharmaceutical Co., Ltd; The manufacturers of Salvia miltiorrhiza ligustrazine injection are Jilin Sichang Pharmaceutical Co., Ltd. and Guizhou Baite Pharmaceutical Co., Ltd; The manufacturers of invert sugar electrolyte injection are Yangzi River Pharmaceutical Group Shanghai haini Pharmaceutical Co., Ltd. and Sichuan Meida kangjiale Pharmaceutical Co., Ltd; The manufacturers of mouse nerve growth factor for injection include shutaishen, Weiming biology, Lizhu pharmaceutical factory of Lizhu group and Wuhan Haite biopharmaceutical Co., Ltd.
In addition, there are many manufacturers of some varieties, such as cerebroprotein hydrolysate, cerebroprotein hydrolysate, alprostadil, etc.
Will price reduction become a trend?
In the view of insiders, adjuvant drugs consume tens of billions of yuan or even hundreds of billions of yuan of medical insurance funds every year. The sharp price reduction trend of adjuvant drugs is inevitable, and the medical insurance funds will gradually tilt to innovation.
For example, this year, the procurement platform of Guangzhou Pharmaceutical Group will carry out GPO procurement for 15 drugs such as recombinant human granulocyte stimulating factor. Among these 15 drugs, alprostadil, oxiracetam, sodium creatine phosphate, etc. are included in the key monitoring catalogue this time.
In this regard, a person from a pharmaceutical enterprise told the Securities Daily that since '4 + 7 city with volume procurement', the price reduction of the pharmaceutical industry has become an overall trend, and adjuvant drugs will also face this trend.